Floatz logo

Inno-206

B-Cell Neoplasm

Curis, Inc.Phase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

47 Active assets in the B-Cell Neoplasm cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
University Hospital, Basel, Switzerland
Phase 2BB
Zanubrutinib
Curis, Inc.
Phase 2BB
PREDNISONE TABLETS
Curis, Inc.
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Curis, Inc.
Phase 2BB
Obinutuzumab
BeOne Medicines
Phase 1/2B

View all 50 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →